Clinical Trial Detail

NCT ID NCT02325557
Title ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
Recruitment Active, not recruiting
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors Advaxis, Inc.
Indications

prostate cancer

Therapies

Pembrolizumab

ADXS31-142

Age Groups: adult

No variant requirements are available.